Literature DB >> 30266821

Identification of IRF8 as a potent tumor suppressor in murine acute promyelocytic leukemia.

Coline Gaillard1, Sangeetha Surianarayanan1, Trevor Bentley1, Matthew R Warr2, Briana Fitch1, Huimin Geng1, Emmanuelle Passegué2, Hugues de Thé3, Scott C Kogan1.   

Abstract

Although the role of promyelocytic leukemia/retinoic acid receptor α (PML/RARA) fusion protein is well recognized in acute promyelocytic leukemia (APL), its contribution to initiation and maintenance of leukemogenesis is not completely understood. Transcriptome analysis in the murine MRP8-PML/RARA APL model has demonstrated modest alterations in gene expression accompanied by expansion of the promyelocyte compartment. Of particular interest, mice expressing PML/RARA showed downregulation of the transcription factor Irf8 mRNA. Interferon regulatory factor 8 (IRF8) is a known regulator of hematopoiesis. Previous research had implicated IRF8 as a tumor suppressor for myeloid neoplasia, and mice lacking IRF8 develop a well-differentiated myeloproliferative neoplasm characterized by expansion of neutrophilic lineage cells. We hypothesized that PML/RARA-mediated downregulation of Irf8 transcript levels contributes to the initiation of APL. We observed significant downregulation of IRF8 protein levels in highly purified promyelocyte populations of PML/RARA transgenic mice. We also found that loss of IRF8 results in expansion of promyelocytes in vivo, partially phenocopying the impact of PML/RARA expression. Moreover, survival experiments showed that complete loss of IRF8 leads to acceleration of APL onset in our PML/RARA mice. Collectively, these data identify IRF8 downregulation as an important factor in APL initiation and highlight a tumor-suppressor role for IRF8 in this acute leukemia.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30266821      PMCID: PMC6177650          DOI: 10.1182/bloodadvances.2018018929

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  21 in total

1.  Irf8 regulates macrophage versus neutrophil fate during zebrafish primitive myelopoiesis.

Authors:  Li Li; Hao Jin; Jin Xu; Yuqian Shi; Zilong Wen
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

2.  ICSBP promoter methylation in myelodysplastic syndromes and acute myeloid leukaemia.

Authors:  N Otto; G Manukjan; G Göhring; W Hofmann; R Scherer; J Chacon Luna; U Lehmann; A Ganser; K Welte; B Schlegelberger; D Steinemann
Journal:  Leukemia       Date:  2011-04-08       Impact factor: 11.528

3.  Molecular signature of retinoic acid treatment in acute promyelocytic leukemia.

Authors:  Natalia Meani; Simone Minardi; Silvia Licciulli; Vania Gelmetti; Francesco Lo Coco; Clara Nervi; Pier Giuseppe Pelicci; Heiko Müller; Myriam Alcalay
Journal:  Oncogene       Date:  2005-05-05       Impact factor: 9.867

4.  SHP1 protein-tyrosine phosphatase inhibits gp91PHOX and p67PHOX expression by inhibiting interaction of PU.1, IRF1, interferon consensus sequence-binding protein, and CREB-binding protein with homologous Cis elements in the CYBB and NCF2 genes.

Authors:  B Kautz; R Kakar; E David; E A Eklund
Journal:  J Biol Chem       Date:  2001-08-01       Impact factor: 5.157

5.  Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias.

Authors:  M Schmidt; S Nagel; J Proba; C Thiede; M Ritter; J F Waring; F Rosenbauer; D Huhn; B Wittig; I Horak; A Neubauer
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

6.  Gamma interferon triggers interaction between ICSBP (IRF-8) and TEL, recruiting the histone deacetylase HDAC3 to the interferon-responsive element.

Authors:  Takeshi Kuwata; Celine Gongora; Yuka Kanno; Kazuyasu Sakaguchi; Tomohiko Tamura; Tomohiko Kanno; Venkatesha Basrur; Robert Martinez; Ettore Appella; Todd Golub; Keiko Ozato
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

7.  Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia.

Authors:  Michelle M Le Beau; Sheila Bitts; Elizabeth M Davis; Scott C Kogan
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

8.  A PMLRARalpha transgene initiates murine acute promyelocytic leukemia.

Authors:  D Brown; S Kogan; E Lagasse; I Weissman; M Alcalay; P G Pelicci; S Atwater; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

9.  IRF8 regulates B-cell lineage specification, commitment, and differentiation.

Authors:  Hongsheng Wang; Chang Hoon Lee; Chenfeng Qi; Prafullakumar Tailor; Jianxun Feng; Sadia Abbasi; Toru Atsumi; Herbert C Morse
Journal:  Blood       Date:  2008-09-17       Impact factor: 22.113

10.  Expression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA mice.

Authors:  Lukas D Wartman; John S Welch; Geoffrey L Uy; Jeffery M Klco; Tamara Lamprecht; Nobish Varghese; Rakesh Nagarajan; Timothy J Ley
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

View more
  6 in total

1.  [Effects of interferon regulatory factor 9 on the biological phenotypes in PML-RARα-induced promyelocytic leukemia].

Authors:  X Yang; H Y Xing; K J Tang; Z Tian; Q Rao; M Wang; J X Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-05-14

2.  Dissection of the MEF2D-IRF8 transcriptional circuit dependency in acute myeloid leukemia.

Authors:  Bianca Y Pingul; Hua Huang; Qingzhou Chen; Fatemeh Alikarami; Zhen Zhang; Jun Qi; Kathrin M Bernt; Shelley L Berger; Zhendong Cao; Junwei Shi
Journal:  iScience       Date:  2022-09-15

Review 3.  Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene.

Authors:  Alessandro Liquori; Mariam Ibañez; Claudia Sargas; Miguel Ángel Sanz; Eva Barragán; José Cervera
Journal:  Cancers (Basel)       Date:  2020-03-08       Impact factor: 6.639

4.  Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia.

Authors:  Isabel Weinhäuser; Diego A Pereira-Martins; Cesar Ortiz; Douglas R Silveira; Luíse A A Simões; Thiago M Bianco; Cleide L Araujo; Luisa C Koury; Raul A M Melo; Rosane I Bittencourt; Katia Pagnano; Ricardo Pasquini; Elenaide C Nunes; Evandro M Fagundes; Ana B Gloria; Fábio Kerbauy; Maria de Lourdes Chauffaille; Armand Keating; Martin S Tallman; Raul C Ribeiro; Richard Dillon; Arnold Ganser; Bob Löwenberg; Peter Valk; Francesco Lo-Coco; Miguel A Sanz; Nancy Berliner; Emanuele Ammatuna; Antonio R Lucena-Araujo; Jan Jacob Schuringa; Eduardo M Rego
Journal:  Cancers (Basel)       Date:  2020-10-27       Impact factor: 6.639

5.  ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency.

Authors:  Zhendong Cao; Krista A Budinich; Hua Huang; Diqiu Ren; Bin Lu; Zhen Zhang; Qingzhou Chen; Yeqiao Zhou; Yu-Han Huang; Fatemeh Alikarami; Molly C Kingsley; Alexandra K Lenard; Aoi Wakabayashi; Eugene Khandros; Will Bailis; Jun Qi; Martin P Carroll; Gerd A Blobel; Robert B Faryabi; Kathrin M Bernt; Shelley L Berger; Junwei Shi
Journal:  Mol Cell       Date:  2021-08-05       Impact factor: 17.970

6.  Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells.

Authors:  Stephanie L Tzetzo; Eduardo Cortes Gomez; Kevin H Eng; Pragya Srivastava; Sheila N Jani Sait; Joseph B Kuechle; Prashant K Singh; Kitty De Jong; Kyle R Wiatrowski; Jennifer Peresie; Ava Dimitroff; Miranda L Lynch; Jianmin Wang; Scott I Abrams; Elizabeth A Griffiths; Michael J Nemeth
Journal:  Leukemia       Date:  2020-02-25       Impact factor: 12.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.